New mid-term targets lift Lonza shares

** Swiss contract drug manufacturer Lonza LONN.S rises 2.2% after setting new mid-term targets and confirming its 2026 outlook

** Lonza targets 10% to 13% organic sales growth and a core EBITDA margin in the high thirties in the medium term

** Vontobel says the updated targets imply some upside to its estimates and sees free cash flow conversion improving

** Zuercher Kantonalbank highlights that the new margin ambitions are significantly higher than the market had expected

** Lonza shares are up around 8% this year, with 24 of 26 analysts rating it “buy” or “strong buy"

($1 = 0.8319 Swiss francs)